Investor Relations

High-growth company with focus on becoming a single-use pure player within all main endoscopy markets.

Latest news

26

Nov. 2021

Ambu wins Danish Design Award

The Ambu® aScope BronchoSampler™ wins prestigious award for improving the workflow and safety of hospital procedures involving lung fluid samples.

Thursday 25 November, the Danish Design Awards 2021 were announced, and Ambu won the award in the category ‘Better Work’ which focuses on how design can contribute to solving workplace challenges thorough innovative and effective solutions.

The award jury said about the aScope BronchoSampler that it “provides a much-improved method for taking samples and performing suction cleaning in lung operations. There are several innovations involved, but mainly the one-handed operation means the procedures can be performed by a single person which is a great design improvement. The solution also reduces the risk of contamination and provides for an overall safer procedure. Until now, there has not been any major changes in these methods since the late 1970s and the development team took a design-led approach to finding a new and simplified solution.

Making a difference for doctors and patients
Ambu’s Chief Innovation Officer, Måns Barsne, comments on the win and emphasizes how the award is the result of a customer-centric approach: “Our goal is to improve healthcare and patient treatment – and the best way to achieve results that make a real difference is to be close to the users. We are proud of the difference this unique device makes for doctors and patients, and to be recognised with a Danish Design Award is an honour. By the way, we do not use ‘unique’ as a buzzword – our device is actually the only solution of its kind.

The aScope BronchoSampler simplifies the clinical procedure of fluid sampling and changes it to a one-man/one-woman job. This can lead to procedure cost-savings, more flexible hospital staff planning and simply a safer procedure for the healthcare professionals to perform. The potential cost savings are for the procedure itself as well as the indirect cost of losing a sample or hospital staff being infected from contact with a patient’s lung fluid.

The aScope BronchoSampler can be used for regular pneumonia patients but is also extremely relevant for COVID-patients with lung problems where there is an increased focus on avoiding cross-contamination.

About the Danish Design Award
Danish Design Award is the major annual Danish design event celebrating the best design solutions and highlighting the many ways in which design can make a difference for our society. Read more and see all Danish Design Award 2021 winners or go directly to Danish Design Award winner: aScope BronchoSampler.

Download
You can download this press release (pdf).

22

Nov. 2021

Ambu announces interim 60-patient clinical trial results for aScope Duodeno 1.5 showing 98.3% procedure success rate

Today, Ambu shares the latest update of its clinical trial results assessing the aScope™ Duodeno 1.5 single-use duodenoscope for ERCP procedures. Following the launch of aScope Duodeno 1.5, Ambu re-started its multi-site clinical trial, and is sharing results from all aScope Duodeno 1.5 cases enrolled to date.

Through 60 cases across all complexity levels, the procedure success rate is 98.3%, meaning 59 of 60 cases were successfully completed using aScope Duodeno 1.5.  Importantly, the one case not completed with aScope Duodeno 1.5 was also not completed with the reusable endoscope.

These interim results add to the growing body of evidence that aScope Duodeno 1.5 meets clinical needs across all ERCP complexity grades, and performs closely in line with reusable duodenoscopes, while completely eliminating the risk of cross-contamination,” says Bassel Rifai, Chief Marketing Officer of Ambu. “With these clinical results, combined with our superior economic proposition, we are confident that aScope Duodeno 1.5 will be the leading choice for health systems that would like to transition to single-use duodenoscopy.

The release today of 60-patient data comes less than two weeks after Ambu shared its 29-patient data. Based on the strong pace of recruitment, Ambu expects to share the results of 150 patients using aScope Duodeno 1.5 around our Q1 earnings release in February 2022 and showcase the results of the study at Digestive Disease Week (DDW) 2022.

With these positive clinical results, Ambu continues its worldwide commercialisation of aScope Duodeno 1.5, with the full launch currently underway across the U.S., Europe, and Australia.

The world’s #1 single-use endoscopy company
Ambu launched the world’s first single-use flexible bronchoscope, the Ambu® aScope™ in 2009. A decade later, in 2021, over 1.5 million Ambu single-use endoscopes were used around the world, and Ambu has now developed scopes for a broad range of clinical areas making Ambu the largest and most innovative supplier of single-use endoscopes, with the #1 position in Pulmonology, ENT, and Urology. Ambu has announced the launch of 20 new devices for single-use endoscopy by end of financial year 2022/23 with the aim of increasing patient safety and improving healthcare workflows.

Download
You can download this press release (pdf).

16

Nov. 2021

Capital increase in connection with exercise of warrants (no. 4)

Ambu A/S issued 770,000 warrants in 2015. Each warrant entitled the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 46 individuals participated in the 2015 scheme.

For the 2015 scheme the vesting period was three years, and the scheme could therefore be exercised in the trading window that opened on 9 November 2021 in connection with Ambu’s Annual Report for 2020/21.

Since 9 November 2021, instructions have been received to exercise warrants as follows:

  • 1 individual has issued instructions to exercise 5,000 warrants at the agreed exercise price of DKK 39.26 per share with a nominal value of DKK 0.50.

Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of the Company’s B shares will be increased by a nominal amount of DKK 2,500 from DKK 111,691,966 to DKK 111,694,466 through the issue of 5,000 Class B shares.

Following this and in consideration of the employees having left the company, no remaining warrants remain under the said 2015 scheme.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 23 November 2021 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788).

Under section 32 of the Danish Capital Markets Act, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

 Number of shares
(nominal value DKK 0.50)
Nominal value
(DKK)
Voting rights
A shares34,320,00017,160,000343,200,000
B shares223,388,932111,694,466223,388,932
Total257,708,932128,854,466566,588,932


Download
You can download this company announcement (pdf).

Latest annual results

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more

Presentations

Get the latest investor presentations and webcasts
Read more

Upcoming events

14

Dec. 2021

Annual General Meeting 2021

Ambu’s annual general meeting will be held on Tuesday 14 December 2021 at 13.00 (CET) at Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, DK-1577 Copenhagen.

16

Dec. 2021

DNB Nordic Healthcare Conference (virtual)

08

Feb. 2022

Earnings release Q1 2021/22

News from Ambu

Sign up and receive financial news and company announcements from Ambu

Sign up

 

keyboard_arrow_up